Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivatuzumab mertansine in advanced SCCHN or esophageal cancer
NCT02254044Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2003
- Primary completion
- Nov 2004
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of bivatuzumab mertansine in squamous cell carcinoma of the head and neck (HNSCC) and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Boehringer Ingelheim. Primary endpoint: Maximum tolerated dose up to 6 months. Started Oct 2003; status: terminated.
02
Drugs
bivatuzumab mertansine
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02254044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254044.